Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
José Luis López-Sendón, Juan García Caldentey, Patricia Trigo Cubillo, et al.
Journal of Neurology (2016) Vol. 263, Iss. 7, pp. 1390-1400
Closed Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

Cannabinoids and the expanded endocannabinoid system in neurological disorders
Luigia Cristino, Tiziana Bisogno, Vincenzo Di Marzo
Nature Reviews Neurology (2019) Vol. 16, Iss. 1, pp. 9-29
Closed Access | Times Cited: 778
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis
Nicola Black, Emily Stockings, Gabrielle Campbell, et al.
The Lancet Psychiatry (2019) Vol. 6, Iss. 12, pp. 995-1010
Open Access | Times Cited: 457
New approaches and challenges to targeting the endocannabinoid system
Vincenzo Di Marzo
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 9, pp. 623-639
Closed Access | Times Cited: 412
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Sarah J. Tabrizi, Michael Flower, Christopher A. Ross, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 10, pp. 529-546
Open Access | Times Cited: 386
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Amir Garakani, James W. Murrough, Rafael C. Freire, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 307
Medical Use of Cannabinoids
Ana Isabel Fraguas‐Sánchez, Ana Isabel Torres‐Suárez
Drugs (2018) Vol. 78, Iss. 16, pp. 1665-1703
Closed Access | Times Cited: 229
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders
Daniel Friedman, Jacqueline A. French, Mauro Maccarrone
The Lancet Neurology (2019) Vol. 18, Iss. 5, pp. 504-512
Closed Access | Times Cited: 185
The Role of Microglia and Astrocytes in Huntington’s Disease
Thulani H. Palpagama, Henry J. Waldvogel, Richard L. M. Faull, et al.
Frontiers in Molecular Neuroscience (2019) Vol. 12
Open Access | Times Cited: 183
Endocannabinoid system in neurodegenerative disorders
Balapal S. Basavarajappa, Madhu Shivakumar, Vikram Joshi, et al.
Journal of Neurochemistry (2017) Vol. 142, Iss. 5, pp. 624-648
Open Access | Times Cited: 182
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications
Ainhoa Bilbao, Rainer Spanagel
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 107
Current and Possible Future Therapeutic Options for Huntington’s Disease
Mackenzie Wendy Ferguson, Connor J. Kennedy, Thulani H. Palpagama, et al.
Journal of Central Nervous System Disease (2022) Vol. 14
Open Access | Times Cited: 80
THC and CBD: Similarities and differences between siblings
Nephi Stella
Neuron (2023) Vol. 111, Iss. 3, pp. 302-327
Open Access | Times Cited: 54
The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation
Mohammad Sobhan Karvandi, Farzam Sheikhzadeh Hesari, Amir Reza Aref, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 45
An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects
Nadia Martínez Naya, Jazmin Kelly, Giuliana Corna, et al.
Molecules (2024) Vol. 29, Iss. 2, pp. 473-473
Open Access | Times Cited: 22
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
Fernanda Fiel Peres, Alvaro C. Lima, Jaime E. C. Hallak, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 156
Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders
Alline C. Campos, Manoela V. Fogaça, Franciele Franco Scarante, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 155
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
Keane Lim, Yuen Mei See, Jimmy Lee
Clinical Psychopharmacology and Neuroscience (2017) Vol. 15, Iss. 4, pp. 301-312
Open Access | Times Cited: 149
Therapeutic approaches to Huntington disease: from the bench to the clinic
Nicholas S. Caron, E. Ray Dorsey, Michael R. Hayden
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 10, pp. 729-750
Closed Access | Times Cited: 147
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Stefania Bonaccorso, A Ricciardi, Caroline Zangani, et al.
NeuroToxicology (2019) Vol. 74, pp. 282-298
Open Access | Times Cited: 142
Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
Emma M. Coppen, Raymund A.C. Roos
Drugs (2016) Vol. 77, Iss. 1, pp. 29-46
Open Access | Times Cited: 123
The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases
Valerio Chiurchiù, Mario van der Stelt, Diego Centonze, et al.
Progress in Neurobiology (2017) Vol. 160, pp. 82-100
Open Access | Times Cited: 116
Alterations in synaptic function and plasticity in Huntington disease
Amy Smith-Dijak, Marja D. Sepers, Lynn A. Raymond
Journal of Neurochemistry (2019) Vol. 150, Iss. 4, pp. 346-365
Open Access | Times Cited: 116
Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity
Xavier Nadal, Carmen del Río, S. Casano, et al.
British Journal of Pharmacology (2017) Vol. 174, Iss. 23, pp. 4263-4276
Open Access | Times Cited: 107
Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases
Dhanush Haspula, Michelle A. Clark
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 20, pp. 7693-7693
Open Access | Times Cited: 102
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system
Marta Aymerich, Ester Aso, Miguel Angel Abellanas, et al.
Biochemical Pharmacology (2018) Vol. 157, pp. 67-84
Open Access | Times Cited: 95
Page 1 - Next Page

Scroll to top